Mangoceuticals (MGRX) Operating Expenses (2023 - 2026)

Mangoceuticals has disclosed Operating Expenses across 4 years of filings, most recently posting $3.2 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $3.2 million, down 31.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.5 million (up 57.73% YoY), and the FY2025 annual result was $18.3 million, up 118.9% from the prior year.
• Operating Expenses came in at $3.2 million for Q1 2026 at Mangoceuticals, up from $415214.0 in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $7.6 million in Q3 2025 to a low of $415214.0 in Q4 2025.
• The 4-year median for Operating Expenses is $2.5 million (2024), against an average of $3.0 million.
• Peak annual rise in Operating Expenses reached 312.54% in 2025, while the deepest fall reached 76.38% in 2025.
• Mangoceuticals' Operating Expenses stood at $2.7 million in 2023, then sank by 35.15% to $1.8 million in 2024, then tumbled by 76.38% to $415214.0 in 2025, then jumped by 659.93% to $3.2 million in 2026.
• The last three Operating Expenses figures came in at $3.2 million (Q1 2026), $415214.0 (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.